Stephen Andrew Welch - 10 Nov 2025 Form 4 Insider Report for Keenova Therapeutics plc

Reporting relationship: EVP & Head of Spec Generics
Issuer ticker: N/A
Reported as of: 10 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Nov 2025, 20:00:19 UTC
Prior SEC filing: 04 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Mark Tyndall, Attorney-in-Fact

Key filing fact

Stephen Andrew Welch filed Form 4 for Keenova Therapeutics plc on 12 Nov 2025.

Key facts

This page summarizes Stephen Andrew Welch's Form 4 filing for Keenova Therapeutics plc.
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Nov 2025, 20:00.

Change

Previous filing in this sequence was filed on 04 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001944355 Primary reporting owner

Welch Stephen Andrew

Relationship: EVP & Head of Spec Generics
Address: 675 MCDONNELL BLVD., HAZELWOOD
Signature: /s/ Mark Tyndall, Attorney-in-Fact
Signature date: 12 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value: $0
Shares: +43,771
Change %
Price: $0.000000
Shares after: 0
Date: 10 Nov 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 43,771
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Stephen Andrew Welch is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

These restricted units were cancelled in connection with the separation of Par Health, Inc. ("Par Health") from the Issuer in exchange for a number of restricted units of Par Health calculated pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health.

SEC remarks

This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.